Rigel autoimmune news

Rigel is reducing headcount by 46 (38%) to about 75 to focus on the launch of fostamatinib. The cuts will mostly come from the research area. Additionally, Donald Payan, a co-founder, retired as EVP, president of discovery and research and as a director. Rigel hired Elson Mayer as EVP and CCO. The company expects the reduction, which will be completed by Dec. 15, to save about $17-$20 million annually. ...